Caveolin-1 Down-Regulation Reduces VEGF-A Secretion Induced by IGF-1 in ARPE-19 Cells.
caveolin-1
endothelial cells
insulin-like growth factor-1
ocular neovascularization
retinal pigment epithelium
vascular endothelial growth factor A
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
28 Dec 2021
28 Dec 2021
Historique:
received:
03
11
2021
revised:
21
12
2021
accepted:
24
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
The insulin-like growth factor 1 (IGF-1) stimulates expression and secretion of vascular endothelial growth factor-A (VEGF-A), the main actor in ocular neovascularization, by RPE cells. Activity of IGF-1 is regulated by interaction between its receptor and Caveolin-1 (Cav-1), the main component of caveolae. The aim of this study was to investigate whether modulation of Cav-1 expression affects synthesis and secretion of VEGF-A. ARPE-19 cells were transfected with small interfering RNA for Cav-1 (si-Cav-1) and with control siRNA (si-CTR) and stimulated with IGF-1. We found that down-regulation of Cav-1 did not affect activation of IGF-1R but regulated in an opposite manner the phosphorylation of Akt and Erk1/2. Moreover, we found that IGF-1 increased mRNA levels of VEGF-A in both si-CTR and in si-Cav-1 ARPE-19 cells and that Cav-1 silencing significantly reduced basal and IGF-1-stimulated VEGF-A release. Then we investigated the response of the microvascular endothelial cell line HMEC-1 to secretory products of ARPE-19 cells by evaluating wound healing closure, finding that conditioned media from si-Cav-1-ARPE-19 cells reduced endothelial cell migration rate. These data demonstrate that Cav-1 regulates secretion of VEGF-A, and that the depletion of Cav-1 reduces IGF-1 induced VEGF-A secretion in ARPE-19 cells and the migratory potential of their secretory products.
Identifiants
pubmed: 35054437
pii: life12010044
doi: 10.3390/life12010044
pmc: PMC8781830
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Mol Endocrinol. 2018 Jul;61(1):T69-T86
pubmed: 29535161
Diabetes. 1997 Oct;46(10):1619-26
pubmed: 9313759
Biochem Biophys Res Commun. 2004 Oct 29;323(4):1203-8
pubmed: 15451424
Am J Physiol Cell Physiol. 2006 Mar;290(3):C832-43
pubmed: 16251472
Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):e58-66
pubmed: 21794046
J Biol Chem. 2016 Mar 18;291(12):6494-506
pubmed: 26814131
J Endocrinol. 2020 Oct;247(1):25-38
pubmed: 32668406
Cytokine. 2017 Jul;95:126-135
pubmed: 28282610
Diabetes Care. 2000 Jan;23(1):80-3
pubmed: 10857973
Physiol Rev. 2005 Jul;85(3):845-81
pubmed: 15987797
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10737-10742
pubmed: 28923916
Biochem Biophys Res Commun. 1993 Jun 15;193(2):631-8
pubmed: 8512562
Int J Mol Sci. 2021 Jun 19;22(12):
pubmed: 34205419
J Invest Dermatol. 2017 Feb;137(2):e11-e16
pubmed: 28110712
Endocrinology. 2008 Feb;149(2):461-5
pubmed: 18039791
Mol Neurobiol. 2018 Mar;55(3):1915-1927
pubmed: 28238097
Curr Eye Res. 2009 Oct;34(10):867-76
pubmed: 19895315
Oxid Med Cell Longev. 2020 Jan 27;2020:9761539
pubmed: 32082483
Am J Pathol. 2014 Feb;184(2):541-55
pubmed: 24326256
J Biol Chem. 2012 May 11;287(20):16424-34
pubmed: 22451674
Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9
pubmed: 11413487
Prog Retin Eye Res. 2017 Jan;56:84-106
pubmed: 27664379
J Mol Neurosci. 2015 Apr;55(4):931-40
pubmed: 25339505
Graefes Arch Clin Exp Ophthalmol. 2009 Nov;247(11):1487-92
pubmed: 19603178
Biochem Biophys Res Commun. 2002 Aug 2;295(5):1085-9
pubmed: 12135605
Biochem Biophys Res Commun. 2004 Mar 26;316(1):240-3
pubmed: 15003536
Nat Med. 1999 Dec;5(12):1390-5
pubmed: 10581081
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):221-229
pubmed: 28114583
J Cell Sci Suppl. 1993;17:189-95
pubmed: 8144697
Invest Ophthalmol Vis Sci. 2003 May;44(5):2192-8
pubmed: 12714661
Br J Pharmacol. 2018 Jan;175(1):125-139
pubmed: 29057462